Lenalidomide Capsule
Product Images NDC 76282-697

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 76282-697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (084916cb Cd26 4942 Bc5b 6d4736594420 01)

Chemical structure of lenalidomide, showing its molecular arrangement with key functional groups including a glutarimide ring and an aminobenzoyl moiety.*

FDA Label Image

1 (084916cb Cd26 4942 Bc5b 6d4736594420 02)

A Kaplan-Meier curve showing progression-free survival probability over time (months) for lenalidomide treatment groups labeled as Rd Continuous, Rd18, and MPT. The y-axis represents survival probability (%) and the x-axis is progression-free survival in months, with a table below indicating the number of subjects at risk at various time points. The graph includes hazard ratios with confidence intervals and a logrank p-value.*

FDA Label Image

2 (084916cb Cd26 4942 Bc5b 6d4736594420 03)

A Kaplan-Meier survival curve chart depicting overall survival probability (%) over time in months for three treatment groups labeled Rd Continuous, Rd18, and MPT. The chart includes a legend with lines in blue (Rd Continuous), green (Rd18), and red (MPT), as well as a table below showing the number of subjects at risk at various time points. Hazard ratios with 95% confidence intervals comparing the groups are noted in the chart area.*

FDA Label Image

3 (084916cb Cd26 4942 Bc5b 6d4736594420 04)

A Kaplan-Meier survival curve chart comparing progression-free survival of lenalidomide versus placebo over months. The chart includes two lines: one for lenalidomide and one for placebo, along with sample sizes and events at risk displayed in a table below the graph.*

FDA Label Image

4 (084916cb Cd26 4942 Bc5b 6d4736594420 05)

A Kaplan-Meier survival curve comparing progression-free survival probability over months between Lenalidomide and placebo groups. The graph plots survival probability on the vertical axis and progression-free survival in months on the horizontal axis. Lenalidomide shows higher survival probability than placebo, with hazard ratio and median survival times noted. The number of subjects at risk is listed below the timeline for both groups.*

FDA Label Image

5 (084916cb Cd26 4942 Bc5b 6d4736594420 06)

A Kaplan-Meier survival curve chart showing time to progression in months on the x-axis and proportion of subjects on the y-axis. The chart compares two groups: Lenalidomide/Dex, which shows higher survival over time, and Placebo/Dex, which shows lower survival. Statistical information including hazard ratio (HR) and confidence intervals are displayed on the graph.*

FDA Label Image

6 (084916cb Cd26 4942 Bc5b 6d4736594420 07)

A Kaplan-Meier survival curve graph showing the proportion of subjects over time to progression in months comparing treatment with Lenalidomide/Dex versus Placebo/Dex. The graph includes hazard ratio with confidence interval and a significant log-rank p-value, illustrating higher progression-free survival in the Lenalidomide/Dex group.*

FDA Label Image

Image-1 (084916cb Cd26 4942 Bc5b 6d4736594420 08)

A Kaplan-Meier survival curve chart showing progression-free survival probability over months for two groups: Rituximab with Lenalidomide versus Rituximab with Placebo. The Y-axis represents survival probability from 0 to 1, and the X-axis shows progression-free survival time in months up to 48. The chart includes a risk table with numbers of subjects at risk at various time points and displays hazard ratio, confidence interval, and log rank p-value statistics.*

FDA Label Image

Container-5mg-genvion (084916cb Cd26 4942 Bc5b 6d4736594420 09)

Label for lenalidomide capsules, 5 mg strength, from Exelan Pharmaceuticals Inc. The label includes the proprietary and generic names, dosage form, strength, and a barcode. The design features a light blue and green color scheme with product information and manufacturer details on a white background.*

FDA Label Image

Container-10mg-genvion (084916cb Cd26 4942 Bc5b 6d4736594420 10)

Label for lenalidomide capsules 10 mg by Exelan Pharmaceuticals Inc. The label shows the proprietary and generic names, strength (10 mg), dosage form (capsule), and manufacturer. It includes regulatory information, a barcode, and a blank unvarnished area for printing.*

FDA Label Image

Container-15mg-genvion (084916cb Cd26 4942 Bc5b 6d4736594420 11)

Label for lenalidomide capsules 15 mg from Exelan Pharmaceuticals Inc. The label shows the proprietary and generic name, dosage strength, capsules form, and manufacturer. Includes usage instructions area and an unvarnished area near the bottom center.*

FDA Label Image

Container-25mg-genvion (084916cb Cd26 4942 Bc5b 6d4736594420 12)

Label for lenalidomide 25 mg capsules, an oral prescription drug by Exelan Pharmaceuticals Inc. The label includes the proprietary and generic name lenalidomide, strength of 25 mg, quantity of 30 capsules, and manufacturer information. Additional text and a barcode are visible on the right side of the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.